Course description

Von Willebrand disease – from theory to clinical practice
- Commissioned education

-An international, case-oriented course
-Course venue: Malmö, Sweden

Target group: Physicians in need of further training in VWD

Course targets – expected results

To use the acquired new knowledge in pathophysiology/diagnostics and the complex area of treatment in von Willebrand disease in the patient in an optimal way.

Improved knowledge about:

- molecular genetic background
- blood coagulation and methods of measurements
- diagnosis
- on demand treatment and prophylaxis
- treatment during surgical operation
- children with von Willebrand disease and aspects on von Willebrand disease in the area gynaecology and obstetrics
- inhibitor development to vWF
- monitoring of vWF patients
- international knowledge about organizations within von Willebrand disease

Good knowledge about modern von Willebrand treatment leads to cost-effective care.

Good knowledge about how to diagnose and treat patients at an early stage and in an optimal way, and how to treat complications, the quality of life for the patients will increase and also the ability to take part in social activities. Ethical and health economy aspects in this patient cohort will also be discussed during the course, which can be important from a social economic perspective.

Course content: See attached programme.

Methodology

The 3-day course will begin with an introduction of VWD through a series of overview lectures. Thereafter, clinical cases will be presented and the management, prognosis, treatment and diagnosis of the disease will be discussed. The course will use an evidence-based approach and participants will review and present scientific articles as well as own abstracts about VWD.

International guidelines for the management of VWD will be distributed. Participants will receive a course binder including the guidelines, articles and lectures, i.e."take home messages".

The course is a collaboration between Malmö Centre for Thrombosis and Haemostasis, Lund University, Skåne University Hospital and Octapharma represented by Nordic.